Harvard Bioscience targets $22.5M–$24.5M Q4 revenue as backlog reaches two-year high, expanding product rollouts and distribution (NASDAQ:HBIO)
Harvard Bioscience(US:HBIO) Seeking Alpha·2025-11-07 07:16Group 1 - The article does not provide any specific information or insights regarding a company or industry [1]